E.g., 01/18/2020
E.g., 01/18/2020
Titlesort ascending Category Credit Event Date Price
Immune Checkpoint Inhibitors in RCC Podcast (2019)
    • 0.50 AMA PRA Category 1 Credit™
    • 0.50 Non-Physician Participation
$0.00 To encourage consistent, high quality, evidence-based treatment of patients, the AUA is launching a series of podcast episodes designed to improve the ability of the urologist to care for patients with prostate, bladder and kidney cancers. These activities are designed to increase the clinician’s competence in the application of new and emerging treatment options, including their mechanism of action and associated side effects.
Highlights in the Medical Management of Urothelial Carcinoma: Non-Muscle Invasive Urothelial Carcinoma (2019)
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 Non-Physician Participation
$0.00 The Live from AUA2019: Highlights in the Medical Management of Urothelial Carcinoma is compromised of two panel discussions filmed at the 2019 AUA Annual Meeting in Chicago focused on optimizing the treatment of urothelial carcinoma.  The panel discussions will present the latest developments in the:1) Management of Non-Muscle Invasive Urothelial Carcinoma 2) Management of Advanced and Metastatic Urothelial Carcinoma (see below for a link to the activity)
Highlights in the Medical Management of Urothelial Carcinoma: Advanced and Metastatic Urothelial Carcinoma (2019)
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 Non-Physician Participation
$0.00 The Live from AUA2019: Highlights in the Medical Management of Urothelial Carcinoma is compromised of two panel discussions filmed at the 2019 AUA Annual Meeting in Chicago focused on optimizing the treatment of urothelial carcinoma.  The panel discussions will present the latest developments in the:1) Management of Non-Muscle Invasive Urothelial Carcinoma (see below for a link to the activity)2) Management of Advanced and Metastatic Urothelial Carcinoma
Highlights in Renal Cell Carcinoma: The Roles of the Urologist and Medical Oncologist (2018)
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 Non-Physician Participation
$0.00 The "Live from AUA2018" Highlights in Renal Cell Carcinoma series is comprised of three panel discussions which will focus on:
Highlights in Renal Cell Carcinoma: The Evolving Landscape of Adjuvant Therapy (2018)
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 Non-Physician Participation
$0.00 The "Live from AUA2018" Highlights in Renal Cell Carcinoma series is comprised of three panel discussions which will focus on:Discussing the evolving landscape of adjuvant therapy for the treatment of kidney cancer and debating the elements of disagreement in this area.Differentiating the roles of urologist and medical oncologist in the care of patients with kidney cancer.Appreciating the patient’s journey through RCC and identifying their needs as it relates to the coordination of care between the urologists and medical oncologists. 
Highlights in Renal Cell Carcinoma: Coordination of Care & the Patient's Journey (2018)
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 Non-Physician Participation
$0.00 The "Live from AUA2018" Highlights in Renal Cell Carcinoma series is comprised of three panel discussions which will focus on:
Highlights from AUA2019: Evolving Role of the Urologist in Metastatic and Castration Resistant Prostate Cancer (2019) $0.00 The AUA is launching an educational initiative to focus on resident and fellow training in the area of Advanced and Castration-Resistant Prostate Cancer. Based on the documented need for additional education in this area, the AUA has developed multiple educational interventions to improve the ability to care for patients with CRPC. These educational activities may also be of interest to advanced practice providers and urologists.
Genetic Testing in Prostate Cancer: Understanding Clinical Implications for Early Detection, Localized Disease & CRPC Webcast 013IC (2019)
    • 2.00 AMA PRA Category 1 Credit™
    • 2.00 Non-Physician Participation
$0.00 There has been a dramatic increase in our understanding of the role of genetic testing in prostate cancer over the last several years. While the clinical impact of BRCA1/2 mutations has been well established in the setting of breast and ovarian cancer with critical implications for treatment (e.g.
Genetic Testing in Prostate Cancer Podcast (2019)
    • 0.50 AMA PRA Category 1 Credit™
    • 0.50 Non-Physician Participation
$0.00 To encourage consistent, high quality, evidence-based treatment of patients, the AUA is launching a series of podcast episodes designed to improve the ability of the urologist to care for patients with prostate, bladder and kidney cancers. These activities are designed to increase the clinician’s competence in the application of new and emerging treatment options, including their mechanism of action and associated side effects.
Fundamentals in Urology Webcast (2019) $655.00 Specifically designed for anyone unable to get away from the office to attend the Live Course, the Webcast option delivers the same great content. Purchase of the Webcast features simultaneous presentation slides and audio recorded from the Live Course and includes access to online course materials.The Fundamentals in Urology course is designed to apply basic science knowledge and principles in development of treatment algorithms. The course has been recently redesigned to 3 days to allow for less time out of the office and in a convenient location for travel. 
Female Sexual Dysfunction for APPs (2017)
    • 2.00 AMA PRA Category 1 Credit™
    • 2.00 Non-Physician Participation
$40.00 Member only benefit! The prevalence of Female Sexual Dysfunction (FSD) a disease encompassing sexual desire and arousal disorders, orgasmic disorders, and sexual pain disorders, is a complex and important clinical issue. In the National Health and Social Life Survey, 43% of women reported some degree of sexual difficulty. There is a disparity in the treatment of sexual dysfunction between women and men that is now correcting.
Evolving Role of the Urologist in Metastatic and Castration Resistant Prostate Cancer: A Guidelines and Case-Based Discussion - Washington, D.C. (...
    • 5.75 AMA PRA Category 1 Credit™
    • 5.75 Non-Physician Participation
12/03/2019 $0.00 Presented by the AUA in partnership with the Society of Urologic Oncology (SUO).
Emerging Treatment Options for Non-Metastatic CRPC Podcast (2018)
    • 0.50 AMA PRA Category 1 Credit™
    • 0.50 Non-Physician Participation
$0.00 To encourage consistent, high quality, evidence-based treatment of patients with Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC), the AUA and Urology Care Foundation has produced a series of online activities and educational resources for healthcare professionals, patients and caregivers. One of those such activities is this complimentary Emerging Treatment Options for Non-Metastatic CRPC Podcast (2018).
Emerging Immunotherapeutic Agents for the Treatment of Bladder Cancer (2017)
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 Non-Physician Participation
$0.00 The AUA developed the Emerging Immunotherapeutic Agents for the Treatment of Bladder Cancer initiative to include multiple educational interventions to improve the urologist, medical oncologist, and other healthcare provider's ability to care for patients with bladder cancer. These activities are designed to increase the clinician's competence in the application of new and emerging treatment options, including the sequencing and associated side effects of those options.
Doppler and Advanced Techniques in Urologic Ultrasound Video (2017)
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 Non-Physician Participation
$125.00 The advanced urologic ultrasound course is designed for participants who have a basic understanding of the physics of ultrasound and some experience with clinical scanning.  This course teaches the physics of Doppler ultrasound and how to use physical principles to improve image quality and understand ultrasound artifacts.  The course is important for those urologists seeking to improve their ultrasound expertise in the operating room and in the office.  

Pages